I am buying $NWBO for $0.25. The fundamentals are good. The biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced recently that it has entered into agreements with a large multi-national corporation for a package transaction involving the Company’s property located near Cambridge, UK. Pursuant to these agreements,
• The Company will sell most of its UK property to the multi-national corporation.
• The Company will receive £37.5 million (approximately $47.3 million) cash payment at closing.
• The Company will retain ownership of 17 acres of the property, which are excluded from the sale and which the Company believes will have substantial additional value in the future.
• The Company will retain a lease-back of the approximately 87,000 square foot manufacturing facility which the Company has been developing on the site, along with substantial adjacent areas, for up to 40 years on favorable terms.